Premium
Predicting Drug‐Resistant Mutations of HIV Protease
Author(s) -
Ishikita Hiroshi,
Warshel Arieh
Publication year - 2008
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.200704178
Subject(s) - protease , human immunodeficiency virus (hiv) , drug resistance , hiv 1 protease , drug , enzyme , mutant , protease inhibitor (pharmacology) , virology , virus , chemistry , drug discovery , biology , biochemistry , microbiology and biotechnology , pharmacology , antiretroviral therapy , viral load , gene
Pièces de résistance : The human immunodeficiency virus (HIV) can acquire drug resistance by mutating the key enzyme HIV protease that is being used as a drug target. A strategy has been developed to predict drug resistance that focuses on the fact that the virus must retain reasonable efficiency for its catalytic reaction while reducing its affinity to the given drug ( γ M : vitality values for the mutant protein M, K i : inhibition constant).